Prime Medicine, Inc. PRME
4.55 USD +0.11 (+2.48%)
At closeNov 3, 2026, 4:29 PM EST
4.55 0.00 0.00%
After hours · Nov 3, 4:29 PM ET
4.44 Day range 4.89
2.67 52-week range 5.91
- YTD
- +31.12%
- 1 year
- -0.22%
Analyst view
Consensus: buy
Buy
Price target (mean) 6.50 +42.9% upside
Now 4.55
- Target (low)
- 4.00
- Target (mean)
- 6.50
- Target (high)
- 10.00
Ratings (0m) 11 7 buy · 4 hold · 0 sell
- Strong buy1
- Buy6
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 12
- 3 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.24724 | -0.33 – -0.21 | -0.44 | +43.8% | 2.80M | +1240.1% | 10 |
| Next quarter | -0.2003 | -0.34 – -0.11 | -0.31 | +35.4% | 3.77M | +72.6% | 10 |
| Current year | -1.17 | -1.45 – -1.06 | -1.65 | +29.3% | 8.73M | +192.5% | 11 |
| Next year | -0.8659 | -1.51 – -0.56 | -1.17 | +25.8% | 24.36M | +179.1% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2025 | Chardan Capital | Maintained | Buy | Buy |
| May 27, 2025 | Citigroup | Downgrade | Buy | Neutral |
| May 20, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| May 20, 2025 | JP Morgan | Downgrade | Overweight | Neutral |
| May 20, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 19, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Mar 20, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 4, 2025 | Citizens Capital Markets | Reiterated | Market Outperform | Market Outperform |
| Mar 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 3, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Dec 10, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Dec 3, 2024 | Guggenheim | Reiterated | Buy | Buy |
| Oct 25, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| May 16, 2024 | Citigroup | Upgrade | Neutral | Buy |
| May 13, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 23, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 22, 2024 | Chardan Capital | Initiated | — | Buy |
| Apr 8, 2024 | TD Cowen | Initiated | — | Buy |
| Apr 3, 2024 | Wedbush | Initiated | — | Outperform |
| Apr 2, 2024 | Wedbush | Initiated | — | Outperform |
| Mar 8, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 5, 2024 | Guggenheim | Maintained | Buy | Buy |
| Dec 8, 2023 | Citigroup | Initiated | — | Neutral |
| Nov 7, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 9, 2023 | BMO Capital | Initiated | — | Outperform |
| Sep 6, 2023 | JonesTrading | Initiated | — | Buy |
| Aug 14, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |